Nektar Therapeutics (NKTR) Stock AnalysisNKTRStock AnalysisNektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Nektar Therapeutics is a good buy right now due to its current price of $72.52, which is significantly below the analyst price target of $153 from Canaccord, indicating a potential upside of 111%. Additionally, the company has a strong cash position of over $1 billion, which secures its financial stability as it progresses through its Phase 3 trials. The main risk is the ongoing litigation with a jury trial scheduled for September 8, which could introduce volatility.

11 analysts cover NKTR: 10 rate it Buy, 1 Hold and 0 Sell. The average price target is 123.43.